# Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin

> **NCT03853421** · PHASE1 · COMPLETED · sponsor: **Modus Therapeutics AB** · enrollment: 24 (actual)

## Conditions studied

- Safety and Tolerability

## Interventions

- **DRUG:** Sevuparin

## Key facts

- **NCT ID:** NCT03853421
- **Lead sponsor:** Modus Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2019-05-06
- **Final completion:** 2019-05-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03853421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03853421, "Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03853421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*